1. Homepage
  2. Equities
  3. Australia
  4. NATIONAL STOCK EXCHANGE OF AUSTRALIA LIMITED
  5. VGI Health Technology Limited
  6. News
  7. Summary
    VTL   AU0000152597

VGI HEALTH TECHNOLOGY LIMITED

(VTL)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

VGI Health Technology Limited (NSX:VTL) Nutraceutical Products Listed on Amazon

01/19/2022 | 05:47pm EDT

Sydney, Australia, Jan 20, 2022 - (ABN Newswire) - Invictus Nutraceuticals, Inc. (Florida, USA), a wholly owned subsidiary of VGI Health Technology Limited (NSX:VTL), is pleased to announce that both NE1-Elite(R) and NE1-Heart(R) are now available for sale on Amazon in the United States.

Amazon invests billions of dollars each year in logistics, tools, services and programs to help sellers build their brand. Invictus Nutraceuticals develops and commercializes nutraceutical products based on two proprietary and patented delivery platforms for improving the bioavailability and efficacy of tocotrienols (a natural product which is one part of vitamin E).

NE1-Elite(R) reduces Delayed Onset Muscle Soreness (DOMS) and improves muscle recovery after workout along with being Informed Sport Certified (banned substance free tested).

NE1-Heart(R) maintains heart health and increases the antioxidant status in the body.

Richard Estalella, the President and CEO of Invictus Nutraceuticals, Inc. said "We are delighted to have Amazon be the foundation of our national online selling business. Being able to leverage Amazon's scale to reach more customers is very exciting and this is a major milestone for the commercialisation of our nutraceutical products."

Invictus Nutraceuticals, Inc. will initiate marketing and promotional programs on the Amazon platform in the near future.


<b>About VGI Health Technology Limited:</b>

VGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

<b>Contact:</b>

Glenn Tong
CEO and Managing Director
Ph: +61 (0) 412 193 350

Andrew Crook
Investor and Media Relations
Ph:+61 (0) 419 788 431

Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200

Copyright (C) 2022 ABN Newswire. All rights reserved., source Press Releases English

All news about VGI HEALTH TECHNOLOGY LIMITED
05/02VGI HEALTH TECHNOLOGY : Extraordinary General Meeting of Shareholders
PU
04/29VGI HEALTH TECHNOLOGY : Update for the period ending 31 March 2022
PU
04/29VGI HEALTH TECHNOLOGY : Quarterly report for the period ending 31 March 2022
PU
04/05VGI HEALTH TECHNOLOGY : Binding sale agreement of subsidiary
PU
04/05VGI HEALTH TECHNOLOGY LIMITED (NSX : VTL) Binding Sale Agreement of Subsidiary
AQ
04/03VGI HEALTH TECHNOLOGY : US Divisional Patent to be granted
PU
04/03VGI Health Technology Limited US Divisional Patent to be Granted
AW
03/20VGI HEALTH TECHNOLOGY LIMITED (NSX : VTL) to Present at American Society for Nutrition Con..
AQ
03/20VGI HEALTH TECHNOLOGY : VTL to present at American Society for Nutrition Conference
PU
03/10VGI HEALTH TECHNOLOGY : 31 December 2021 Half Year Audit Reviewed Financial Statements
PU
More news
Financials
Sales 2021 - - -
Net income 2021 -3,90 M -2,76 M -2,76 M
Net cash 2021 0,02 M 0,01 M 0,01 M
P/E ratio 2021 -7,08x
Yield 2021 -
Capitalization 13,8 M 9,77 M 9,77 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees -
Free-Float 0,87%
Chart VGI HEALTH TECHNOLOGY LIMITED
Duration : Period :
VGI Health Technology Limited Technical Analysis Chart | VTL | AU0000152597 | MarketScreener
Income Statement Evolution
Managers and Directors
Glenn Tong CEO, Managing Director & Executive Director
Ian Forbes Chief Financial Officer
Louis James Panaccio Independent Non-Executive Chairman
David Kingston Chief Scientific Officer
Jiayi Yu Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
VGI HEALTH TECHNOLOGY LIMITED-60.00%10
GILEAD SCIENCES, INC.-11.38%80 715
REGENERON PHARMACEUTICALS, INC.8.63%73 916
VERTEX PHARMACEUTICALS22.26%68 665
WUXI APPTEC CO., LTD.-22.20%40 017
BIONTECH SE-40.07%37 546